Appointment of Dr. Leanne Rowe AM to Board of Directors
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce the appointment of Dr. Leanne Rowe AM as a Non-Executive Director of the Company.

Dr. Rowe, MD, MB, BS, FRACGP, Dip. RACOG, FAICD, currently serves as Deputy Chancellor of Monash University, one of Australia’s leading universities, with over 55,000 students in Australia and overseas and annual revenues in excess of $1.3 billion. She is an immediate past Chairman of the Royal Australian College of General Practitioners, an organisation representing Australian General Practice with a membership of over 15,000 GPs, and played an important and varied role in transforming the status of that organisation.

Dr. Rowe also serves on the Boards of various companies including GMHBA Ltd., a Private Health Fund with annual revenue in excess of $115 million and over 70,000 members, where she consults on a number of preventive health programs relating to diabetes, heart disease and cancer in regional areas of Australia. Other board and high level committee positions have included the Victorian Medical Women’s Society and Victorian Health Minister’s Council on Medical Workforce.

Dr. Rowe currently serves as a health consultant working as an associate with a number of Melbourne based consultancy companies evaluating national programs and she is leading a national initiative on medical workplace violence across all medical organisations. She is also an Adjunct Associate Professor at the University of Sydney, has previously held a wide range of roles in the field of medical education and has written numerous publications.

In addition to her current roles, Dr. Rowe has extensive past experience across a variety of areas in medicine and surgery, including community medicine, adolescent health, emergency medicine and postnatal care.

The Board of Directors is extremely pleased to welcome her as a colleague and believes that she will bring a wealth of directly relevant experience to the Company.